Selective Transvenous Chemoembolization of Primary Pancreatic Tumors

Inclusion Criteria: * Age ≥ 18 years * Pathologically and radiologically-confirmed pancreatic adenocarcinoma confined to the pancreas with initial diagnosis within 8 weeks of consent * Resectable, borderline-resectable or locally-advanced primary pancreatic adenocarcinoma per NCCN guidelines * The patient is deemed a candidate for the study by the Johns Hopkins Multidisciplinary Pancreatic Tumor Board * Preserved liver function (Child-Pugh A-B class) without significant liver decompensation * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 at study entry * Measurable or evaluable disease that will be directly treated with intra-pancreatic therapy (as defined by Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\] * Suitable for PRVI, based on blood parameters such as platelet count, LFTs including bilirubin and coagulation status including international normalized ratio (see "Exclusion Criteria" below) * The patient is able to give informed consent * The patient, if a woman of childbearing potential, has a negative pregnancy test * The patient is willing and able to comply with study procedures, scheduled visits, and treatment plans * Life expectancy of at least 3 months Exclusion Criteria: * Serum total bilirubin \> 3.0 mg/dL * Creatinine \> 2.0 mg/dL * Platelets \< 75,000/μL * Hgb \< 8.0 g/dl * ANC ≤ 1,000/μL * INR \> 2.0 * Complete portal vein thrombosis or significant cavernous transformation of the portal vein * Ascites (trace ascites on imaging is OK) * The patient is pregnant or breast-feeding * The patient is allergic to contrast media that cannot be readily managed or prevented with premedication * Patients with peripheral neuropathy \[\> grade 1, according to the National Cancer Institute Common Toxicity Criteria v5.0 (CTAE v5.0)\]